Recent news that Halifax-based Immunovaccine (TSXV:IMV) was pulling its proposed public financing du... Read More
Robust M&A activity drove overall sector valuations in fiscal 2013, and we believe expectations ... Read More
Byron Capital analyst Douglas Loe says that ramped up marketing expenses aren’t hitting... Read More
Byron Capital analyst Douglas Loe says the results Novadaq Technologies (Novaday Technologies... Read More
This morning, Novadaq (TSX:NDQ) reported its 2012 Q4 and full year results. The company’s $23-... Read More
Share
Tweet
pin
Share